Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Diphtheria tetanus pertussis-hepatitis B vaccine - GSK

Drug Profile

Diphtheria tetanus pertussis-hepatitis B vaccine - GSK

Alternative Names: Diphtheria-tetanus-pertussis-hep B vaccine (Tritanrix-HepB) - GSK; DPT + Hepa B vaccine - GSK; DTPw-HBV vaccine - GSK; Tritanrix HB - GSK; Tritanrix HepB; Tritanrix-HepB

Latest Information Update: 02 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GSK
  • Class Bacterial vaccines; Hepatitis B vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Diphtheria; Hepatitis B; Pertussis; Tetanus

Most Recent Events

  • 20 Dec 2013 The Committee for Medicinal Products for Human Use (CHMP) of the EMA adopts a positive scientific opinion in accordance with Article 58 of Regulation (EC) No 726/2004 for Tritanrix® HB for immunisation against diphtheria, tetanus pertussis and hepatitis B in infants from 6 weeks onwards
  • 05 May 2011 Launched for Diphtheria in India (IM)
  • 05 May 2011 Launched for Diphtheria in Vietnam (IM)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top